BioPharma Resources

Therapeutic area

Immunology and inflammation

Psoriasis, atopic dermatitis, rheumatoid arthritis, IBD and lupus. Drugs are placed in areas by keyword matches on their FDA pharmacologic class and approved use, and trials by their listed conditions, so a few land in the wrong area.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations

Approvals since 2023

30

Originals, plus breakthrough or accelerated new uses

Recruiting Phase 2

139

Industry-sponsored

Recruiting Phase 3

90

Industry-sponsored

Recruiting Phase 4 (post-approval)

15

Industry-sponsored

Recent approvals

All
  • Jakafi Xr (Ruxolitinib Phosphate) · Incyte Corp OrphanMay 1, 2026
  • Icotyde (Icotrokinra Hydrochloride) · Janssen Biotech NovelPriority reviewMar 17, 2026

    To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy

  • Adquey (Difamilast) · Acrotech Biopharma NovelFeb 12, 2026

    To treat mild to moderate atopic dermatitis

  • Avtozma (Tocilizumab-Anoh) · Celltrion INC Jan 21, 2026
  • Rhapsido (Remibrutinib) · Novartis NovelPriority reviewSep 30, 2025

    To treat chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment

  • Anzupgo (Delgocitinib) · Leo Pharma As NovelJul 23, 2025

    To treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response

  • Starjemza (Ustekinumab-Hmny) · Bio-Thera Solutions LTD May 22, 2025
  • Steqeyma (Ustekinumab-Stba) · Celltrion, Inc. Apr 30, 2025
  • Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTD Apr 30, 2025
  • Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTD Apr 30, 2025
  • Otulfi (Ustekinumab-Aauz) · Fresenius Kabi USA Apr 30, 2025
  • Tyenne (Tocilizumab-Aazg) · Fresenius Kabi USA Mar 14, 2025
  • Avtozma (Tocilizumab-Anoh) · Celltrion INC Jan 24, 2025
  • Steqeyma (Ustekinumab-Stba) · Celltrion, Inc. Dec 17, 2024
  • Dupixent (Dupilumab) · Regeneron Pharmaceuticals Breakthrough therapyPriority reviewSep 27, 2024

Recruiting trials by phase

Industry-sponsored drug and biologic trials.

Most approvals since then, by company

Drugs in development

Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.

All
  • IanalumabVAY736, VAY736 AIPhase 318 trials

    Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome

  • ZasocitinibTAK- 279, NDI-034858Phase 317 trials

    Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease

  • AfimkibartRO7790121, RVT-3101Phase 312 trials

    Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis

  • PovorcitinibINCB054707, INCB54707Phase 312 trials

    Incyte · Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis

  • MK-7240PRA023, TulisokibartPhase 310 trials

    Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease

  • AZD0120GC012FPhase 39 trials

    AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis

  • CM512Phase 39 trials

    Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma

  • FrexalimabSAR441344Phase 39 trials

    Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion

  • HSK44459Phase 39 trials

    Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis

  • LP-003SinglePhase 39 trials

    Longbio Pharma · Allergic Asthma, Chronic Spontaneous Urticaria (CSU), Peanut Allergies

  • hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials

    Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)

  • LutikizumabABT-981Phase 38 trials

    AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis

  • OlatorepatideHS-20094Phase 38 trials

    Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes

  • PF-07275315tilrekimigPhase 38 trials

    Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease

  • SHR-1819Phase 38 trials

    Guangdong Hengrui Pharmaceutical Co., Ltd · Seasonal Allergic Rhinitis, Moderate to Severe Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis

Largest recruiting Phase 3 trials

All

More: Immunology and inflammation news · literature

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.